Research Project
Combined ImMunotherapy against ovarian cancer: new therapeUtic approach based on anti-IL-6/IL-6R mAbs and NK adoptIve cell transfer therapy (CIMULI) (Ministerio de Ciencia e Innovación, Spain). Principal investigators: Araceli Tobío Ageitos & Anxo Vidal Figueroa.
Project description
Ovarian cancer is the 7th most common cancer in women and the most lethal gynecological malignancy worldwide with a 5-year survival. Although advances in chemotherapy protocols, only modest progress has been obtained in prolonging survival, making necessary the search of new therapeutic approaches. Immunotherapies are definitely transforming cancer treatment in solid malignant tumours. In this sense, the purpose of CIMULI’s research project is to study novel therapeutic agents’ effectiveness, based on combined immunotherapy including adoptive cell transfer and anti-IL-6/IL6R monoclonal antibodies.
Profile, requirements & experience
- Degree in Biology, Biochemistry, Biotechnology, Chemistry, Pharmacy, Medicine or related topic.
- Availability to enroll in a Doctorate Program (academic year 2024-2025).
Further, we will positively evaluate the following experience and duties:
- Molecular biology techniques (western blot, flow cytometry, microscopy) and cell culture protocols.
- Tumoral models and preclinical research.
- Immunotherapy protocols (monoclonal antibodies’ treatment, adoptive cell therapies, etc).
- English skills.
Job offer
- We offer 1-year predoctoral contract (starting from: September 2024).
- The candidate will design and develop the experiments of CIMULI’s research project in a dynamic, international and translational research group.
- Applications will be open until August 9th 2024.
If you are interested, please send us a copy of your CV and motivation letter (1 page max.) to araceli.tobio.ageitos@usc.es.